

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression; psychosis	Serotonin (5-HT ₆) receptor; serotonin (5-HT ₇) receptor; dopamine D2 receptor	<i>In vitro</i> and rat studies suggest inhibitors of 5-HT ₆ , 5-HT ₇ and dopamine D2 receptors could help treat psychosis and depression in patients with dementia. Chemical synthesis of arylsulfonamide-benzoxazole analogs identified several compounds as selective nanomolar inhibitors of the three receptors. In two rat models of drug-induced hyperactivity, one lead compound decreased hyperlocomotive activity compared with vehicle without also causing sedation or memory impairment. In a rat model of forced swim-induced depression, the lead compound decreased immobility compared with vehicle. Ongoing preclinical work by Adamed Group includes developing the lead compound, AD-N03, to treat depression and psychosis.	Patented by Adamed; available for licensing	Kolaczowski, M. <i>et al.</i> <i>J. Med. Chem.</i> ; published online May 7, 2014; doi:10.1021/jm401895u Contact: Marcin Kolaczowski, Adamed Group, Czosnow, Poland e-mail: marcin.kolaczowski@adamed.com.pl
		SciBX 7(20); doi:10.1038/scibx.2014.589 Published online May 22, 2014		